(Q37182025)

18 August 2017

1 reference

title

Sexual dimorphism of humoral immunity with human vaccines (English)

1 reference

18 August 2017

1 reference

1 reference

Ian Francis Cook

1

1 reference

PubMed ID

18524433

18 August 2017

language of work or name

English

0 references

publication date

9 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

26

1 reference

18 August 2017

29-30

1 reference

18 August 2017

3551-3555

1 reference

Approaching the asymptote? Evolution and revolution in immunology

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Effector and memory T-cell differentiation: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Invited review: sex ratio and rheumatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Gender, age, and ethnicity in HIV vaccine-related research and clinical trials: report from a WHO-UNAIDS consultation, 26-28 August 2004. Lausanne, Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunologic correlates of protection induced by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Vaccination against the major infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immune response to influenza vaccination in community-dwelling Chinese elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Effect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002-2005 influenza periods.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Eccentric exercise as an adjuvant to influenza vaccination in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Acute stress exposure prior to influenza vaccination enhances antibody response in women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

The association between life events, social support, and antibody status following thymus-dependent and thymus-independent vaccinations in healthy young adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/hepatitis B vaccination in 242 adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity of combined hepatitis A and B vaccine in elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Simultaneous active and passive immunization against hepatitis A studied in a population of travellers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Response to hepatitis A vaccine in HIV-positive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Clinical trial with inactivated hepatitis A vaccine and recommendations for its use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Hepatitis A vaccine failure: how to treat the threat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Hepatitis A vaccine failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Acute hepatitis A despite regular vaccination against hepatitis A and B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunization against hepatitis B--what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Hepatitis B Vaccination in Diabetic Patients: Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Hepatitis B vaccine responsiveness in Connecticut public safety personnel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity of a recombinant hepatitis B vaccine in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Clinical evaluation of a recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Long term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Factors associated with hepatitis B vaccine response among dentists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Intradermal hepatitis B vaccination in a large hospital employee population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Development and persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Hepatitis B vaccine: immune responses in haemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Timing of hepatitis B vaccination: its effect on vaccine response in health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

High rate of seroconversion following administration of a single supplementary dose of recombinant hepatitis B vaccine in Iranian healthy nonresponder neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Female children respond to recombinant hepatitis B vaccine with a higher titre than male

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Comparative immunogenicity of hepatitis B vaccine administered into the ventrogluteal area and anterolateral thigh in infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with nonalcoholic Native and non-Native controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Impact of nutritional status on antibody responses to different vaccines in undernourished Gambian children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Impact of Pneumococcal Vaccination on Morbidity and Mortality of Geriatric Patients: A Case-Controlled Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Effect on diphtheria immunity of combined tetanus and diphtheria booster vaccination in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Booster effect of low doses of tetanus toxoid in elderly vaccinees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Epidemic diphtheria in Belarus, 1992-1997

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Epidemiology of epidemic diphtheria in three regions, Russia, 1994-1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Reduced seroconversion to measles in infants given vitamin A with measles vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Sex differences in the humoral antibody response to live measles vaccine in young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Child mortality following standard, medium or high titre measles immunization in West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Meningococcal A vaccination response is enhanced by acute stress in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

The immunological response to polyvalent meningococcal vaccine in Bauchi State, Nigeria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunological sex differences. A study of patients with rheumatoid arthritis, their relatives, and controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunity to diphtheria in adults in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Immunity to diphtheria among children in Northern Norway and North-Western Russia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

T-lymphocyte subsets in West African children: impact of age, sex, and season.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Genetic control of the CD4/CD8 T-cell ratio in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Normal values of CD4 and CD8 lymphocyte subsets in healthy indian adults and the effects of sex, age, ethnicity, and smoking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Sex hormones as immunomodulators in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

Progesterone and the immunology of pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

A hepatitis B vaccination program in a community teaching hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

inferred from DOI database lookup

7 January 2021

based on heuristic

Tetanus Prophylaxis and Circulating Antitoxin in Men and Women.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.054

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.04.054

1 reference

18 August 2017

1 reference

PubMed ID

18524433